Get the Stockscreener App
4.65
80.23%
2.07
After Hours:
4.15
-0.50
-10.75%
Lipella Pharmaceuticals Inc stock is traded at $4.65, with a volume of 86.70M.
It is up +80.23% in the last 24 hours and up +30.25% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$2.58
Open:
$6.6
24h Volume:
86.70M
Relative Volume:
60.58
Market Cap:
$5.62M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-6.20
EPS:
-0.75
Net Cash Flow:
$-3.46M
1W Performance:
+74.16%
1M Performance:
+30.25%
6M Performance:
-4.24%
1Y Performance:
-39.45%
1-Day Range:
$4.07
$7.31
1-Week Range:
$2.50
$7.31
52-Week Range:
$2.21
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Compare LIPO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
4.65 | 5.62M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Offerings News Live Feed - StockTitan
Stock market news: Lipella Pharmaceuticals +96.90%, Digital Turbine +66.19% among top gainers as investors assess corporate earnings report - Business Upturn
Stock market news: Lottery.com surged by 93.55% while Lipella Pharmaceuticals posted rise of 86.44% during mid day trading - Business Upturn
Strong Earnings Drive Digital Turbine (APPS) Stock’s Market Rally - Stocks Telegraph
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook - Benzinga
Clinical Trials News Live Feed - StockTitan
Stock market today: Lipella Pharmaceuticals +99.22%, Digital Turbine +68.90% among top gainers in early trading - Business Upturn
Dow Edges Higher; US Weekly Jobless Claims Increase - Benzinga
Stock market today: Lipella Pharmaceuticals jumped by 98.06% whereas ReTo Eco-Solutions plunged by 38.75% in early trading - Business Upturn
FDA Greenlight Sends Lipella Pharma Stock Skyrocketing 160% - Wall Street Pit
Lipella Pharmaceuticals (LIPO) Stock Sees Strong Pre-Market Rally - Stocks Telegraph
FDA approves Lipella's oral treatment access program - Investing.com
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewswire
Revolutionary Oral Disease Treatment Gets FDA Early Access Approval6M Americans Could Benefit - StockTitan
Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment - Mugglehead
Full Stock Market News from 2025-02-01 - StockTitan
Graft Versus Host Disease FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight - Barchart
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com - Defense World
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 - MSN
Lipella Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Biden-Harris Administration Awards Record-Breaking $183B in Federal Contracts to Small Businesses, Marking Fourth Consecutive Year of Growth - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement - GlobeNewswire Inc.
Lipella Pharmaceuticals Inc. Announces Second Closing of Offering 2024 - Defense World
SABBY MANAGEMENT, LLC Acquires 60,325 Shares in Lipella Pharmace - GuruFocus.com
Elevai Labs (NASDAQ:ELAB) Announces Resignation of Director - Defense World
Lipella Pharmaceuticals Inc. Enters into Agreement with Spartan Capital Securities, LLC and Closes Initial OfferingThe pharmaceutical company Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) recently disclosed in an 8-K filing with the U.S. Securities and - Defense World
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewswire
Lipella Pharmaceuticals Cancels Special Meeting Due to Lack of Quorum - Defense World
CMC Pharmaceuticals - Contract Pharma
Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times
Lipella Pharmaceuticals Enters into Placement Agent and Consulting Agreements - Defense World
Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com
Lipella Pharmaceuticals reschedules special meeting - Investing.com
Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan
Critical Review: Lipella Pharmaceuticals (LIPO) & Its Peers - Defense World
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):